Trial Profile

A Phase 1b Dose-escalating Study With RBT-9 in Healthy Volunteers and Subjects With Chronic Kidney Disease Stage 3-4

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Stannous protoporphyrin (Primary)
Indications Acute kidney injury; Renal failure
Focus Biomarker; Therapeutic Use
Sponsors Renibus Therapeutics

Most Recent Events

18 Nov 2020 Status changed from active, no longer recruiting to completed.
19 Oct 2020 According to a Renibus Therapeutics media release, data from the study will be presented at the American Society of Nephrology (ASN) Kidney Week 2020 virtual meeting.
22 Apr 2020 Planned End Date changed from 31 Jan 2020 to 31 Oct 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com